The Latest Breaking News from Eli Lilly

Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

MarketBeat · Jul 8, 2025

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:LLY) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its…

Benzinga · Jul 7, 2025

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

The Independent UK · Jul 7, 2025

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.

MarketBeat · May 29, 2025

Is Eli Lilly and Company Stock Underperforming the Dow?

While Eli Lilly has underperformed the Dow over the past year, analysts remain bullish about the stock’s prospects.

Barchart · May 29, 2025

5 High-Potential Stocks That Could Have Your Investments Rising Quickly

The stock market doesn’t hand out guarantees. But every so often, a few companies show signs of powerful upward movement due to innovation, market shifts,...

Saving Advice · May 27, 2025

The TGA has approved donanemab for Alzheimer’s disease. How does this drug work and who will be able to access it?

This week, Australia’s Therapeutic Goods Administration (TGA) approved a drug called donanemab for people in the early stages of Alzheimer’s disease.

The Conversation · May 23, 2025

Australia approves new drug to treat early Alzheimer’s disease

Kisunla is first new treatment registered by TGA in 25 years but could cost patients more than $80,000 and less than one in five will be eligible

The Guardian - AU · May 22, 2025

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’

Cramer explains why this pharmaceutical company is a buy as it outperforms a key rival.

Barchart · May 17, 2025

Ozempic-maker Novo Nordisk Says CEO To Step Down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

International Business Times · May 16, 2025